UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

The New England journal of medicine, 2014-06, Vol.370 (23), p.2169-2179

2014

Volltextzugriff (PDF)

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales

Microbiology spectrum, 2022-02, Vol.10 (1), p.e0235921-e0235921

2022

Volltextzugriff (PDF)

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection

The western journal of emergency medicine, 2020-07, Vol.21 (4), p.943-948

2020

Volltextzugriff (PDF)

The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients

PloS one, 2012-11, Vol.7 (11), p.e49578-e49578

2012

Volltextzugriff (PDF)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs

Drugs in Context, 2018-12, Vol.7, p.212559-10

2018

Volltextzugriff (PDF)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

Clinical infectious diseases, 2016-03, Vol.62 (5), p.545-551

2016

Volltextzugriff (PDF)

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

Antimicrobial agents and chemotherapy, 2015-04, Vol.59 (4), p.1849-1855

2015

Volltextzugriff (PDF)

Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation

Cell, 2022-08, Vol.185 (16), p.2879-2898.e24

2022

Volltextzugriff (PDF)

227. Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates

Journal of clinical microbiology, 2023-07, Vol.61 (7), p.e0024623-e0024623

2023

Volltextzugriff (PDF)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial

Clinical infectious diseases, 2023-01, Vol.76 (1), p.78-88

2023

Volltextzugriff (PDF)

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

Clinical infectious diseases, 2023-01, Vol.76 (1), p.66-77

2023

Volltextzugriff (PDF)

15863 Development of natural bacteriophages for skin care

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB48-AB48

2020

Volltextzugriff (PDF)

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program

Journal of antimicrobial chemotherapy, 2023-06, Vol.78 (6), p.1406-1414

2023

Volltextzugriff (PDF)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

Drug safety, 2016-02, Vol.39 (2), p.147-157

2016

Volltextzugriff (PDF)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

Antimicrobial agents and chemotherapy, 2019-11, Vol.63 (11)

2019

Volltextzugriff (PDF)

Applying Desirability of Outcome Ranking End Points

Clinical infectious diseases, 2023-07, Vol.77 (1), p.159-161

2023

Volltextzugriff (PDF)

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections

Clinical infectious diseases, 2023-06, Vol.76 (12), p.2213-2215

2023

Volltextzugriff (PDF)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety

Open forum infectious diseases, 2019-01, Vol.6 (1), p.ofy331

2019

Volltextzugriff (PDF)

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

Antimicrobial agents and chemotherapy, 2015-08, Vol.59 (8), p.5007-5009

2015

Volltextzugriff (PDF)

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age

The Pediatric infectious disease journal, 2015-07, Vol.34 (7), p.748-752

2015

Volltextzugriff (PDF)

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis

Journal of antimicrobial chemotherapy, 2016-02, Vol.71 (2), p.460-463

2016

Volltextzugriff (PDF)

Abstract PR07: Novel phages targeting the intratumor-associated bacteria Fusobacterium nucleatum

Cancer research (Chicago, Ill.), 2020-04, Vol.80 (8_Supplement), p.PR07-PR07

2020

Volltextzugriff (PDF)

A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study

BMC infectious diseases, 2013-11, Vol.13 (1), p.561-561, Article 561

2013

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(54)
Buchkapitel
(1)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Humans
(23)
Microbiology
(15)
Infectious Diseases
(14)
Female
(13)
Male
(13)
Teicoplanin - Analogs & Derivatives
(12)
Dalbavancin
(10)
Adult
(9)
Middle Aged
(9)
Teicoplanin - Administration & Dosage
(9)
Anti-Bacterial Agents - Administration & Dosage
(8)
Immunology
(8)
Pharmacology & Pharmacy
(8)
Anti-Bacterial Agents - Therapeutic Use
(7)
Skin
(7)
Staphylococcus Aureus
(7)
Teicoplanin - Adverse Effects
(7)
Aged
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection

The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation

227. Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

15863 Development of natural bacteriophages for skin care

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

Applying Desirability of Outcome Ranking End Points

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis

Abstract PR07: Novel phages targeting the intratumor-associated bacteria Fusobacterium nucleatum

A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study

Suchergebnisse filtern